Nexvet Biopharma plc Announces Pricing of Initial Public Offering
February 05 2015 - 5:30AM
Veterinary biologic therapy developer Nexvet Biopharma
(Nasdaq:NVET) today announced the pricing of its initial public
offering of 4,000,000 ordinary shares at a price to the public of
$10.00 per share. The shares are expected to begin trading on the
NASDAQ Global Market on February 5, 2015 under the ticker symbol
"NVET." All of the ordinary shares are being offered by Nexvet. In
addition, Nexvet has granted the underwriters a 30-day option to
purchase up to an additional 600,000 ordinary shares.
BofA Merrill Lynch and Cowen and Company are acting as joint
lead book-running managers for the offering. Piper Jaffray and JMP
Securities are acting as co-managers.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission. The offering is being made only by means of a
written prospectus forming part of the effective registration
statement. Copies of the final prospectus related to the offering
may be obtained, when available, from BofA Merrill Lynch, 222
Broadway, New York, NY 10038, Attention: Prospectus Department,
e-mail: dg.prospectus_requests@baml.com, or from Cowen and Company,
LLC, c/o Broadridge Financial Services, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by
calling 631-274-2806, or by faxing 631-254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful.
CONTACT: Investors
Candice Knoll
cknoll@bplifescience.com
415.375.3340 Ext. 105
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jun 2024 to Jul 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jul 2023 to Jul 2024